pharmaceuticals

Lilly's triple-receptor weight-loss drug retatrutide heads to FDA with a 24 percent efficacy edge over rivals and a $1,200 price target from JPMorgan.

President Trump's plan to impose 100 percent tariffs on imported generic drugs by 2028 would double prices for medications that fill nine of 10 U.S. prescriptions.

The platform's expansion to 300 new generic drugs directly challenges Big Pharma and pharmacy benefit managers, aiming to cut consumer costs

Presidential remarks at White House briefing trigger market speculation about new infectious disease funding

Global health declaration triggers immediate funding release as pharmaceutical companies prepare for major procurement contracts from U.S. and international agencies

Belgian pharma group UCB's substantial acquisition of Candid Therapeutics underscores how prevailing interest rate conditions and broader economic stability are shaping corporate M&A strategies and capital deployment.

The nation's highest court faces a critical decision on mail-order abortion pills, potentially reshaping the pharmaceutical market and igniting a new wave of political spending.

Senator Bernie Sanders is compelling Senate Republicans to take a public stand on President Trump's pharmaceutical pricing agreements, aiming to highlight the industry's significant lobbying influence and campaign contributions.

The White House's unprecedented tariff threat on branded pharmaceuticals forces a reckoning for global drugmakers, demanding domestic manufacturing or steep levies.

President Trump's selective pharmaceutical levies, exempting cooperating firms, introduce a nuanced risk profile for branded drug manufacturers, prompting re-evaluation of sector-specific credit and equity exposures without broad market contagion.